Market Research Report
Europe Polymerase Chain Reaction Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||837252|
|Published||Content info||80 Pages
Delivery time: 2-3 business days
|Europe Polymerase Chain Reaction Market Forecast 2019-2027|
|Published: May 13, 2019||Content info: 80 Pages||
The Europe polymerase chain reaction market generated a revenue of $XX million in 2018 and is projected to reach $XX million by 2027, at a CAGR of 6.21% through 2019-2027. The rising number of end users in proteomics and genomics market is boosting the growth of the conventional PCR machines in the Europe market.
The countries of France, Spain, Italy, United Kingdom, Germany and the remaining countries formulating the Rest of Europe regional segment are considered for the market study. Increasing competition coupled with price burden will outlay the PCR market. The rising awareness among end-users regarding usage of the PCR. However, the high costs associated with the required reagents and consumables is a major concern which will be hampering the growth of the market in the Europe region.
The German market for PCR is driven by the increasing demand of PCR tests for detection of infectious diseases like tuberculosis which is rampant in the country. The rising aging population is the key factor for the market expansion in Germany.
The major companies operating in the market are Pacific Biosciences of California, Inc., Qiagen N.V., F. Hoffman La Roche Ltd., Becton Dickinson Biosciences Systems and Reagents Inc., Siemens Healthineers, Fluidigm Corporation, MDXhealth Corporation, Nano Biosys Inc., Biomerieux SA, Bio-Rad Technologies Inc., Danaher Corporation, Tahara Bio Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., and Abbott Laboratories, which have been thoroughly summed up in the report.